News | August 11, 2021
Sequent Scientific net profit at Rs 87.30 lakh in Q1FY22
Formulation business grew by 15 per cent in the quarter
Formulation business grew by 15 per cent in the quarter
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
A globally approved pen filled by mass technology provides a safer self- administration fertility solution
Company working on COVID vaccine INO 4800
Deal signed with AOP Orphan for US commercial rights
A veteran in cell therapy and oncology commercialisation
The drug is indicated for mild and transient episodes of heart block
Partnership enables broad reach of cfDNA methylation blood tests for early cancer detection
Phase II trial will evaluate the safety and efficacy of ASC40 in patients with moderate to severe acne
Both companies aim to improve the efficiency and success rate of the current drug discovery process.
Subscribe To Our Newsletter & Stay Updated
